Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

Journal of Medical Economics, 2016 05: 1-17. doi: 10.1080/13696998.2016.1187151

o assess the cost-effectiveness of ceritinib vs alternatives in patients who discontinue treatment with crizotinib in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) from a Canadian public healthcare perspective.

View abstract

Authors

Hurry M, Zhou ZY, Zhang J, Zhang C, Liangyi F, Rebeira M, Xie J